{"transactions":[{"id":931955,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-24T01:05:44.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":false,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029."}],"balance_after":365000,"derivative":{"exercise_price":3.08,"expiration_date":"2036-01-23","underlying":"Common Shares","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0000912282-26-000119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000119/form4.xml","form_type":"4"}},{"id":977285,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":false,"shares":25280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents grant of 225,000 employee stock options on February 2, 2023, which vest in equal monthly installments at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, with full vesting on the fourth annual anniversary of the vesting commencement date."}],"balance_after":199720,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Shares","underlying_shares":25280},"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977284,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":false,"shares":2271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents grant of 103,500 employee stock options on May 19, 2022, which vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":45168,"derivative":{"exercise_price":0.55,"expiration_date":"2032-05-22","underlying":"Common Shares","underlying_shares":2271},"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977283,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":true,"shares":25280,"price":0.94,"value":23763.2,"ownership":{"direct":true},"balance_after":361827,"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":977282,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-12-08T13:12:05.000Z","date":"2025-12-05","kind":"exercise","planned":false,"acquired":true,"shares":2271,"price":0.55,"value":1249.05,"ownership":{"direct":true},"balance_after":336547,"source":{"system":"sec-edgar","filing":"0000912282-25-001370","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225001370/form4.xml","form_type":"4"}},{"id":1103425,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"officer":true,"officer_title":"CBO, COO & CCO"}}],"security":"Warrants","published_at":"2025-06-23T12:48:00.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":37736,"price":0.125,"value":4717.0,"ownership":{"direct":true},"balance_after":37736,"derivative":{"exercise_price":1.2,"exercise_date":"2025-06-18","expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":37736},"source":{"system":"sec-edgar","filing":"0000912282-25-000697","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000697/form4.xml","form_type":"4"}},{"id":1103424,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"officer":true,"officer_title":"CBO, COO & CCO"}}],"security":"Common Shares","published_at":"2025-06-23T12:48:00.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":37736,"price":1.2,"value":45283.2,"ownership":{"direct":true},"balance_after":334276,"source":{"system":"sec-edgar","filing":"0000912282-25-000697","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000697/form4.xml","form_type":"4"}},{"id":1273447,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO, COO and CCO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-11T22:41:41.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":450000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-003613","document":"form4-02112025_100238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925003613/form4-02112025_100238.xml","form_type":"4"}},{"id":1426254,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":23565,"price":0.63,"value":14845.95,"ownership":{"direct":true},"balance_after":296540,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426253,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.62,"value":3100.0,"ownership":{"direct":true},"balance_after":272975,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426252,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":2280,"price":0.61,"value":1390.8,"ownership":{"direct":true},"balance_after":267975,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426251,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":3424,"price":0.6,"value":2054.4,"ownership":{"direct":true},"balance_after":265695,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":0.61,"value":1525.0,"ownership":{"direct":true},"balance_after":262271,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1426249,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-08-21T22:38:07.000Z","date":"2024-08-19","kind":"purchase","planned":false,"acquired":true,"shares":2155,"price":0.58,"value":1249.9,"ownership":{"direct":true},"balance_after":259771,"source":{"system":"sec-edgar","filing":"0001415889-24-021869","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924021869/form4-08212024_100803.xml","form_type":"4"}},{"id":1489390,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-05T18:37:39.000Z","date":"2024-06-04","kind":"exercise","planned":false,"acquired":false,"shares":56061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":47439,"derivative":{"exercise_price":0.55,"expiration_date":"2032-03-27","underlying":"Common Stock","underlying_shares":56061},"source":{"system":"sec-edgar","filing":"0001415889-24-015533","document":"form4-06052024_060635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924015533/form4-06052024_060635.xml","form_type":"4"}},{"id":1489389,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Common Stock","published_at":"2024-06-05T18:37:39.000Z","date":"2024-06-04","kind":"exercise","planned":false,"acquired":true,"shares":56061,"price":0.55,"value":30833.55,"ownership":{"direct":true},"balance_after":257616,"source":{"system":"sec-edgar","filing":"0001415889-24-015533","document":"form4-06052024_060635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924015533/form4-06052024_060635.xml","form_type":"4"}},{"id":1660682,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER AND COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-02T22:53:07.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":600000,"derivative":{"exercise_price":1.31,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001415889-24-002379","document":"form4-02022024_100258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924002379/form4-02022024_100258.xml","form_type":"4"}},{"id":1754595,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer and COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-26T21:54:48.000Z","date":"2023-10-24","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the option shall vest and become exercisable on each monthly anniversary of the vesting commencement date of October 23, 2023."}],"balance_after":75000,"derivative":{"exercise_price":0.99,"expiration_date":"2033-10-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-053695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123053695/doc4.xml","form_type":"4"}},{"id":1811659,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-09T22:21:38.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":71762,"price":1.22,"value":87549.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":201555,"source":{"system":"sec-edgar","filing":"0001209191-23-045234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123045234/doc4.xml","form_type":"4"}},{"id":2035048,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-02T23:29:28.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":225000,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-23-006394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123006394/doc4.xml","form_type":"4"}},{"id":2252689,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-05-27T21:34:18.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":113569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest monthly, subject to continued service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":129793,"source":{"system":"sec-edgar","filing":"0001209191-22-032672","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122032672/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-23"}},{"id":2259362,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-24T00:07:34.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":353656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":353656,"derivative":{"exercise_price":2.98,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":353656},"source":{"system":"sec-edgar","filing":"0001209191-22-031498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122031498/doc4.xml","form_type":"4"}},{"id":2259361,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-24T00:07:34.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":103500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 1,136,600 shares of Novosteo common stock for $0.05 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":103500,"derivative":{"exercise_price":0.55,"expiration_date":"2032-03-27","underlying":"Common Stock","underlying_shares":103500},"source":{"system":"sec-edgar","filing":"0001209191-22-031498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122031498/doc4.xml","form_type":"4"}},{"id":2259360,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68858,"kind":"person","name":"Hannah Brendan","position":1,"cik":"0001929422","reported_name":"Hannah Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-05-24T00:07:34.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":16224,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":16224,"source":{"system":"sec-edgar","filing":"0001209191-22-031498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122031498/doc4.xml","form_type":"4"}}]}